Posos is an advanced artificial intelligence platform dedicated to medical prescriptions. Pulse 2.0 interviewed Posos co-founder and CEO Emmanuel Bilbault to learn more about the company.
Emmanuel Bilbault’s Background
What is Bilbault’s background? Bilbault said:
“I’m a pharmacist by training and grew up as ‘the doctor’s son’ in a small village in France. My father was a beloved family doctor who was constantly on-call for his patients. This instilled in me a deep appreciation for healthcare and inspired me to become a pharmacist myself. I worked closely with doctors, seeing firsthand the complexities and time pressures involved in prescribing optimally for each patient.”
Formation Of Posos
How did the idea for Posos come together? Bilbault shared:
“As a pharmacist, I was frustrated by the inefficiencies in the prescribing process. Doctors are under immense time pressure, making it challenging to thoroughly evaluate the latest medical knowledge against each unique patient case. This can lead to relying on familiar prescription patterns rather than fully personalizing every treatment plan.”
“Doctors face a daunting task in cross-referencing the latest medical knowledge against a patient’s profile to determine the ideal treatment plan. I recognized that doctors needed support to optimize prescribing within their limited time. I envisioned an AI tool that could simplify the process by rapidly cross-referencing patient data with up-to-date clinical information and seamlessly integrating recommendations into the existing workflow. That spark evolved into Posos and our mission to humanize healthcare with intelligent technology.”
Core Products
What are the company’s core products and features? Bilbault explained:
“Posos’ flagship offering is an AI-powered prescribing assistant. It streamlines the process via voice recognition and image capture of printed scripts. Our advanced algorithms then analyze the prescription and cross-reference it against our comprehensive medical database and the patient’s records. Within seconds, it provides personalized recommendations to correct inappropriate dosage or drug choice and enhance efficiency. It is supported by the first multilingual, AI-powered drug database structured for global interoperability.”
Challenges Faced
What challenges has Bilbault and the team face in building the company? Bilbault acknowledged:
“Healthcare is a complex industry with high barriers to entry. We overcame this by building strong partnerships with medical experts and software publishers. Obtaining certification from both France’s health authorities, HAS, and EU regulatory agency were major milestones that opened doors. Compliance and cybersecurity are also critical challenges we address rigorously. But our greatest asset is our team of doctors, pharmacists and engineers who enable us to create solutions that blend medical expertise with advanced technology.”
Evolution Of Posos’ Technology
How has the company’s technology evolved since launching? Bilbault noted:
“When we started, our focus was scanning and transcribing paper scripts into the EHR data format. As our AI capabilities advanced, we developed more sophisticated features like voice recognition, real-time prescription analysis and recommendations tailored following the patient profile. Our latest milestone is the release of a unique AI-assisted multilingual drug database that is interoperable with medical terminologies in any language. This is not only the support of our prescribing assistant but it will also enable any EHR publisher to expand globally with its software and bring benefits to practitioners and patients worldwide.”
Significant Milestones
What have been some of the company’s most significant milestones? Bilbault cited:
“Recent successes include partnerships with EU and US EHR publishers and major university hospitals. Our medical database receiving the French Health Authorities (Haute Autorité de Santé) approval was a major achievement as no one has obtained it over the last 30 years. We are also proud of our international AI research award in north America last summer during the ACL Conference. But our proudest moments are hearing from doctors how Posos has helped them improve patient care.”
Customer Success Stories
After asking Bilbault about customer success stories, he revealed:
“One general practitioner used Posos to save his father-in-law from a life-threatening drug interaction, by uncovering a safer alternative drug recommendation. In hospitals, anesthesiologists often wasted 5+ minutes manually transcribing paper scripts into the electronic patient records. Posos eliminated this burden, allowing fast, accurate prescription capture into their system. “
Differentiation From The Competition
What differentiates the company from its competition? Bilbault affirmed:
“Our unrivaled medical database and seamless integration into clinical workflows makes Posos truly unique. Legacy drug databases are text-based and country-specific. Ours has been entirely structured and built with SNOMED terminology using AI. This powers advanced and more tailored decision support and global scalability unmatched by any competitor. Our solutions enhance workflows rather than disrupting them, driving high clinician adoption.”
Future Company Goals
What are some of the company’s future company goals? Bilbault concluded:
“We want to make our AI assistant available to every clinicians whatever his language or country, starting with Europe and North America. We also aim to enhance our analytics capabilities to cross-check more data types, including pharmacogenetic and biological data, so as to provide more dynamic and predictive recommendations. Most importantly, we strive to make prescription optimization effortless so that doctors can focus on patient relationships. The more digital, the more human medicine becomes.”
